Cretostimogene grenadenorepvec - CG Oncology
Alternative Names: CG-0070Latest Information Update: 28 Aug 2024
At a glance
- Originator Cell Genesys; Genetic Therapy
- Developer CG Oncolgy; Lepu Biopharma
- Class Antineoplastics; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Granulocyte macrophage colony stimulating factor agonists; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Bladder cancer
- No development reported Solid tumours
Most Recent Events
- 23 Aug 2024 CG Oncology plans a phase II trial for Bladder cancer (Treatment-naive) (Intravesicular) in September 2024 (NCT06567743)
- 12 Jun 2024 CG Oncology initiates an expanded-access programme for Bladder cancer in USA (NCT06443944)
- 24 May 2024 Updated efficacy data from the phase II CORE-001 trial in Bladder cancer released by CG Oncolgy